HCP
RIGL icon

Hexagon Capital Partners’s Rigel Pharmaceuticals RIGL Stock Holding History

Hexagon Capital Partners’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2
Closed -$36 – 1346
2025
Q1 		$36 Hold
2
– – ﹤0.01% 1816
2024
Q4 		$34 Hold
2
– – ﹤0.01% 1824
2024
Q3 		$32 Hold
2
– – ﹤0.01% 1563
2024
Q2 		$17 Hold
2
– – ﹤0.01% 1445
2024
Q1 		$33 Hold
2
– – ﹤0.01% 1454
2023
Q4 		$32 Hold
2
– – ﹤0.01% 1408
2023
Q3 		$24 Hold
2
– – ﹤0.01% 1401
2023
Q2 		$28 Hold
2
– – ﹤0.01% 1413
2023
Q1 		$29 Hold
2
– – ﹤0.01% 1436
2022
Q4 		$33 Hold
2
– – ﹤0.01% 1442
2022
Q3 		$0 Hold
2
– – ﹤0.01% 1409
2022
Q2 		$0 Hold
2
– – ﹤0.01% 1234
2022
Q1 		$0 Hold
2
– – ﹤0.01% 975
2021
Q4 		$0 Hold
2
– – ﹤0.01% 890
2021
Q3 		$0 Buy
+2
New +$79 ﹤0.01% 882

Other funds holding RIGL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CLGM
Capitolis Liquid Global Markets New York $15.7B AUM 30.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Hexagon Capital Partners's RIGL Position: Q2 2025 in Review

Hexagon Capital Partners sold out of Rigel Pharmaceuticals (RIGL) in Q2 2025, closing a stake of 2 shares — an estimated $36 sold.

Hexagon Capital Partners first reported a position in RIGL in Q3 2021 and held it in 15 quarters. The position peaked at $36 in Q1 2025. 125 funds tracked by Wall St. Rank hold RIGL as of Q2 2025.

  • Hexagon Capital Partners reported no remaining Rigel Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Hexagon Capital Partners sold 2 Rigel Pharmaceuticals shares in Q2 2025, an estimated $36.
  • Hexagon Capital Partners first reported a position in Rigel Pharmaceuticals in Q3 2021 and held it in 15 quarters.
  • Hexagon Capital Partners's Rigel Pharmaceuticals position peaked at $36 in Q1 2025.
  • 125 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2025.

Based on Hexagon Capital Partners's 13F filing for Q2 2025, filed 11 Aug 2025.